Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2016, Article ID 1316326, 4 pages
Research Article

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions

Vibrance Skin Clinic, 412 Pearls Best Height II, Behind Max Hospital, Netaji Subhash Place, Pitampura, Delhi 110034, India

Received 21 January 2016; Revised 14 April 2016; Accepted 28 July 2016

Academic Editor: Elizabeth H. Kemp

Copyright © 2016 Vinay Singh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Psoriasis is a common, chronic, immune mediated, inflammatory disease of skin characterized by red patches enclosed with white scales and affects 2-3% of people in the world. Topical therapy, phototherapy, and systemic therapy were employed for management of disease from many last decades. However, long term uses of these agents are associated with unwanted effects and toxicities. Recently, Itolizumab has been developed as world’s first anti-CD6 humanized monoclonal IgG1 antibody for the management of moderate-to-severe chronic plaque psoriasis in India. Here we are presenting the response indicated by Itolizumab in 7 Indian patients having moderate-to-severe psoriasis with severe comorbidities and who were intolerant/nonresponding to conventional therapies.